Dazhi Yang

Dr. Dazhi Yang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Pain Research and Management
Verified
Journal Article
Open access
PDF file
YLYufeng Long
Yufeng Long
WYWeihong Yi
Weihong Yi
DYDazhi Yang
Dazhi Yang
Osteoporotic vertebral compression fracture (OVCF) is a common cause of pain and disability and is steadily increasing due to the growth of the elderly population. To date, percutaneous vertebroplasty (PVP) and percutaneous kyphoplasty (PKP) are almost universally accepted as appropriate vertebral augmentation procedures for OVCFs. There are many advantages of vertebral augmentation, such as short surgical time, performance under local anaesthesia, and rapid pain relief. However, there are certain issues regarding the utilization of these vertebral augmentations, such as loss of vertebral height, cement leakage, and adjacent vertebral refracture. Hence, the treatment for OVCF has changed in recent years. Satisfactory clinical results have been obtained worldwide after application of the OsseoFix System, the SpineJack System, radiofrequency kyphoplasty of the vertebral body, and the Kiva VCF treatment system. The following review discusses the development of the current techniques used for vertebral augmentation.


24 November 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ZQZhenqian Qi
Zhenqian Qi
JLJiayi Luo
Jiayi Luo
ZXZheng Xiao
Zheng Xiao
DYDazhi Yang
Dazhi Yang
Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass and deterioration of the bone microarchitecture, resulting in an increased risk of fragility fractures. Emerging evidence underscores the crucial role of immune cells as central regulators of bone metabolism. Various immune cells, including T lymphocytes and their subsets, such as TH1, TH2, TH17, and Treg cells, as well as B lymphocytes, macrophages, dendritic cells, neutrophils, mast cells, and eosinophils, orchestrate bone remodeling through complex mechanisms. These mechanisms include direct and indirect regulation of osteoclast differentiation and osteoblast function, often mediated by cytokine networks. For example, T-cell subsets exert diverse and sometimes opposing effects, whereas B cells modulate the RANKL/OPG axis. Macrophages exhibit a biphasic role, with pro-inflammatory M1 and anti-inflammatory M2 phenotypes differentially influencing bone homeostasis. This review synthesizes current knowledge on the functional contributions of immune cells to osteoporosis pathogenesis, highlighting their therapeutic potential for innovative treatment strategies.

18 August 2020 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
PLPeng Luo
Peng Luo
LYLan Yu
Lan Yu
QLQiang Lin
Qiang Lin
CWChangde Wang
Changde Wang
DYDazhi Yang
Dazhi Yang
STShuo Tang
Shuo Tang
The aim of this study was to prepare a promising biomaterial for bone tissue repair and regeneration. The Strontium – calcium sulfate hemihydrate (Sr-α-CaS) scaffold incorporating gelatin microspheres (GMs) encapsulated with Ginsenoside Rg1 (Rg1) was designed. The scaffolds of Rg1/GMs/Sr-α-CaS showed sustained release of Rg1, good biocompatibility and ability of promoting osteogenic differentiation and angiogenesis in vitro. The scaffolds were implanted into animal model of cranial bone defect to characterize bone tissue repair and regeneration in vivo. From the images of Micro-CT, it was obvious that the most bone tissue was formed in Rg1/GMs/Sr-α-CaS group in 12 weeks. New bone structure, collagen and mineralization were analyzed with staining of HE, Masson and Safranin O-Fast green and showed good distribution. The expression of osteocalcin of Rg1/GMs/Sr-α-CaS indicated new bone formation in defect site. The results revealed that synergy of Rg1 and Sr showed the best effect of bone repair and regeneration, which provided a new candidate for bone defect repair in clinic.

28 January 2023 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
DYDazhi Yang
Dazhi Yang
JTJie Tan
Jie Tan
YLYufeng Long
Yufeng Long
KHKang Huang
Kang Huang
WHWeidong Han
Weidong Han
WYWeihong Yi
Weihong Yi
Background: Percutaneous vertebroplasty was the most common strategy for osteoporotic vertebral compression fracture. However, refracture after vertebroplasty also occurred and bone mineral density (BMD) was one of the main factors associated with refracture after percutaneous vertebroplasty. Aims: To investigate the efficacy of a short-sequential treatment of teriparatide followed by alendronate on prevention of refracture after percutaneous vertebroplasty in osteoporotic patients, and compare it with the therapy of alendronate alone. Methods: From January 2018 to January 2020, we recruited 165 female osteoporosis patients after percutaneous vertebroplasty who were assigned into sequential treatment of teriparatide followed by alendronate group (TPTD + ALN group) and alendronate alone group (ALN group). The vertebral fracture occurred during this process was also recorded in both the groups. A total of 105 participants completed the 1-year follow-up. Furthermore, BMD and serum procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were compared between the two groups during 1-year follow-up. Results: The 105 patients were finally included, with 59 in ALN group and 46 in TPTD + ALN group. During 1-year follow-up, the vertebral refracture rate in TPTD + ALN group was much lower than that in ALN group (2.2% vs. 13.6%, p < 0.05). At 12 months, the BMDs at lumbar in TPTD + ALN group were significantly elevated when compared to the ALN group (0.65 ± 0.10 vs. 0.57 ± 0.07, p < 0.001). Discussion and conclusion: A short-sequential administration of teriparatide followed by alendronate was more effective in elevating the BMD and decreasing the refracture rate at 12-month follow-up, compared to the counterpart with alendronate alone.

4 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
KHKang Huang
Kang Huang
TPTudi Pang
Tudi Pang
CTChangjun Tong
Changjun Tong
HCHouqing Chen
Houqing Chen
YNYupeng Nie
Yupeng Nie
DYDazhi Yang
Dazhi Yang
DHEA‐Box Helicase 37 (DHX37) is a putative RNA helicase. It is involved in various RNA secondary structure alteration processes, including translation, nuclear splicing, and ribosome assembly. It is reported to be associated with the neurodevelopmental disorder with brain anomalies, and a recent study suggests that DHX37 is a functional regulator of CD8 T cells. Dysregulation of the CD8 T cell function is closely related to defective antitumor immune responses. In the present study, we investigated the expression, mutation, and prognostic role of DHX37 in human cancers, mainly by mining publicly available datasets. Our results suggested that DHX37 was significantly upregulated in 17 kinds of tumors. Mutations including deletions, insertions, and substitutions of DHX37 were widely detected. Besides, the expression of DHX37 was negatively correlated with immune‐related genes PD‐L1, RGS16, and TOX, and it was positively associated with TIM3, LAG3, and NCOR2. Through biofunctional analysis, we observed that DHX37 was significantly enriched in cancer‐related pathways such as cell cycle, DNA replication, mismatch repair, RNA degradation, and RNA polymerase. In conclusion, the study explored the significance of DHX37 in human cancers. DHX37 may serve as a potential target for cancer immunotherapy.